The volunteers will have blood samples taken to test the generation of immunity by July 30, and data about vaccine safety and immunity is set to be available by mid-September.
The trials of Nano Covax will then continue on another 12,000 volunteers.
Nano Covax has been developed by the Nanogen Pharmaceutical Biotechnology JSC since May 2020.